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Hepatitis C virus (HCV) and its sequelae present a significant source of economic and socie-
tal burden. Introduction of highly effective curative therapies has made HCV elimination
attainable. The study used a predictive model to assess the clinical and economic impact of
implementing national screening and treatment policies toward HCV elimination in Korea.
Methods
A previously validated Markov disease progression model of HCV infection was employed
to analyze the clinical and economic impact of various strategies for HCV diagnosis and
treatment in Korea. In this analysis, the model compared the clinical and economic out-
comes of current HCV-related interventions in Korea (7,000 patients treated and 4,200
patients newly diagnosed annually, starting in 2017) to four elimination scenarios: 1) initiat-
ing sufficient diagnosis and treatment interventions to meet the World Health Organization’s
GHSS elimination targets by 2030, 2) delaying initiation of interventions by one year, 3)
delaying initiation of interventions by two years and 4) accelerating initiation of interventions
to meet elimination targets by 2025. Modelled historical incidence of HCV was calibrated to
match a viremic HCV prevalence of 0.44% in 2009. Elimination scenarios required 24,000
treatments and 34,000 newly diagnosed patients annually, starting in 2018, to reach the
2030 targets.
Results
Compared to current “status quo” interventions, elimination (or accelerated elimination by
2025) would avert 23,700 (27,000) incident cases of HCV, 1,300 (1,400) liver-related deaths
(LRDs) and 2,900 (3,100) cases of end-stage liver disease (ESLD) over the 2017–2030
time period. Postponing interventions by one (or two) years would avert 21,100 (18,600)
new HCV infections, 920 (660) LRDs and 2,000 (1,400) cases of ESLD by 2030. Following
elimination or accelerated elimination strategies would save 860 million USD or 1.1 billion
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USD by 2030, respectively, compared to the status quo, requiring an up-front investment in
prevention that decreases spending on liver-related complications and death.
Conclusions
By projecting the impact of interventions and tracking progress toward GHSS elimination
targets using modelling, we demonstrate that Korea can prevent significant morbidity, mor-
tality and spending on HCV. Results should serve as the backbone for policy and decision-
making, demonstrating how aggressive prevention measures are designed to reduce future
costs and increase the health of the public.
Introduction
Chronic hepatitis C (CHC) is a leading cause of liver disease affecting 71 million people in
2017, representing 1% of the global population [1]. Hepatitis C virus (HCV) has received
increased attention in South Korea (hereafter Korea) in recent years due to a notable number
of healthcare-associated outbreaks reported between 2015 and 2016, associated with unsafe
injection practices [2]. Due to factors including delayed viral identification, absence of a vac-
cine, costly treatment and the lack of a national database for HCV in Korea, CHC infection
has proliferated in the Korean population, and only recent advancements have been able to
estimate the true disease burden. In 2009, the anti-HCV prevalence in the adult Korean popu-
lation was 0.78% (approximately 385,000 anti-HCV cases) [3].
The introduction of direct-acting antiviral agents (DAAs) with a�90% cure rate in 2014
caused a dramatic shift in CHC awareness and treatment and has made HCV elimination
possible. As such, the World Health Organization introduced Global Health Sector Strategy
(GHSS) targets for the elimination of HCV as a public health threat by 2030, including 1) a
90% reduction in incident cases of CHC, 2) a 65% reduction in HCV-related deaths, 3) diagno-
sis of 90% of chronic infections and 4) treatment of 80% of eligible people with CHC [4]. Prior
to the launch of DAA regimens (which were approved by the national healthcare system in
Korea in 2015), only 14% of Korean CHC patients were estimated to have received treatment
with an interferon-based antiviral regimen over a 5-year period [5]. Today, pan-genotypic reg-
imens are reimbursable without restrictions (i.e. patients of all fibrosis stages are eligible for
treatment).
Due to the largely asymptomatic nature of HCV, infections are often diagnosed after the
manifestation of late-stage complications. Late-stage disease can be exponentially more expen-
sive to manage and treat, which is an incentive to screen and diagnose patients in earlier stages
of disease. Currently, there is no systematic screening system to find asymptomatic CHC
patients in Korea. Up to 75% of HCV-infected Koreans are unaware of their infection and
potential to transmit; therefore, screening and treatment are integral components of a plan
toward elimination [6]. A predictive model was used to inform national screening and treat-
ment policies to achieve HCV elimination in Korea. The primary objectives were to 1) report
the current state of HCV management in Korea (status quo) and 2) identify the clinical and eco-
nomic efforts required for Korea to be on track to eliminate HCV by 2030.
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Methods
This analysis was based on a previously published Markov disease progression model that fore-
casts the annual HCV-infected population in a country or region by stage of liver disease, sex
and age [7]. The Impact of Inaction (IOI) model, used in the present analysis, is a streamlined
version of the disease progression model with the added features of population scalability and
economic analysis. Korean demographic, epidemiological and economic data on HCV disease
burden and spending were input into the model to quantify the disease burden and medical
costs associated with CHC infection and its sequelae. Various intervention scenarios were
modelled to assess the clinical and economic impact of delaying the diagnosis and treatment of
HCV infection. This study was designed from the Korean formal healthcare sector perspective
with a target population of all HCV-infected Koreans. Study parameters were analyzed over a
14-year time horizon of 2017–2030. All costs were discounted at the annual rate of 3%.
Model structure
The Microsoft Excel1 based disease burden model, developed by the Center for Disease Anal-
ysis (CDA), tracks the sex- and age-structured HCV-infected population from incidence
through stages of liver disease (fibrosis (F0–F3 on the METAVIR scale), compensated cirrho-
sis, decompensated cirrhosis, hepatocellular carcinoma and liver transplantation) to eventual
death (all-cause or HCV-liver-related). The validation of modelled outcomes has been previ-
ously published [7].
HCV epidemiology and healthcare cost data
In 2009, there were about 49.4 million inhabitants in Korea, with an estimated 216,000 RNA
positive cases of HCV (0.44% viremic prevalence). This was calculated by adjusting an anti-
HCV prevalence of 0.78% by 56.1% viremia (Table 1) [3]. Modelled historical incidence of
HCV was calibrated to match the reported prevalence. The diagnosis coverage was estimated
at 30%, or 64,800 HCV-infected people [6]. Currently in Korea, HCV treatment is reimbursed
for all fibrosis stages, and there is no age limit for treatment eligibility. From 2010 through
2015, 4,600 patients were treated annually [8]. The national estimate of a 90% sustained viro-
logic response at 12 weeks or more post-treatment (SVR12) was assumed.
The Korean healthcare system provides universal coverage for all inhabitants of Korea
following at least six months of residency. The Korean National Health Insurance System
(KNHIS) captures all healthcare visits and claims data and is therefore considered representa-
tive of the HCV-infected population seeking healthcare in Korea [14]. Cases of HCV-related
death and end-stage liver disease (ESLD) indicators (decompensated cirrhosis (DC), liver
transplants (LT) and hepatocellular carcinoma (HCC)) extracted from the KNHIS system
were used to calculate average cost data.
Average annual spending on laboratory testing, treatment and diagnosis of liver-related
complications and extra-hepatic manifestations (EHM) were calculated from the 2017 KNHIS
claims database. The cost of treating HCV extrahepatic manifestations used in this study is
based on data from the KNHIS (Study Number: NHIS-2019-1-140). The 2017 cost data were
extracted for patients with either a principal diagnosis-I or sub diagnosis-I of CHC or EHM.
The ICD-10-CM Code used for CHC was B18.2. A maximum of three EHM diagnoses per
patient were considered in the calculation of EHM-related costs. HCV treatment (including
treatment assessment and monitoring) costs were estimated at 9,540 USD per patient, and the
cost of HCV diagnostic testing was 12 USD (Table 1). Prices for all healthcare services in
Korea are fixed by KNHIS and therefore uniform across all cases. Outpatient and inpatient
service costs are equal as all HCV-related costs are paid for by public funds.
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Scenario development
Five scenarios were developed to estimate the impact of various interventions on the disease
burden of CHC in Korea. The status quo served as a baseline to calculate cases of ESLD and
HCV-related deaths averted by 2030 for each elimination scenario. For the status quo scenario,
over 2016–2020, a 50% reduction in the number of treated patients was applied to simulate the
expected depletion of diagnosed patients and patients under care in the first few years of DAA
treatment, a trend demonstrated across Western countries. The status quo scenario did not
meet GHSS elimination targets, therefore, four elimination scenarios were designed to meet
these targets while also taking into consideration the impact of delayed intervention [4].
Elimination scenarios were modelled with changes to the start year of intervention, number
of diagnosed cases and number of cases treated (Table 2). Unless specified below, elimination
scenarios assumed a SVR12 of 90%, treatment eligibility for all ages and were designed to meet
GHSS elimination targets by 2030. The five modelled scenarios are as follows:
1. Status quo: Modelled from the most recent available national data (starting in 2017), esti-
mating 4,200 newly diagnosed patients and 7,000 patients treated annually.
2. Standard elimination: 24,000 newly diagnosed patients and 34,000 patients treated annu-
ally, beginning in 2018.
3. One-year delayed elimination: 24,000 newly diagnosed patients and 34,000 patients
treated annually, beginning in 2019.
Table 1. HCV-related inputs for Korean impact of inaction disease burden model.
Category Item Year Value Source
Disease burden model parameters Anti-HCV prevalence 2009 0.78% [3]
Viremic rate (HCV-RNA positive) 2009 56.1% [3]
Viremic diagnosed 2009 64,800 (30% diagnosis coverage) [6]
Genotype distribution 2013 52.7% genotype 1 [9]
Treated 2010–2017 7,000 in 2017 [8]
Liver transplants 1992–2000, 2000–2012 1,200 in 2013 [10, 11]
Liver transplants due to HCV 2009–2013 5% [10]
Diagnostic and laboratory costs per test (USD) Anti-HCV test 2016 12 [12]
RNA/ PCR test 2016 90 [12]
HCV genotyping 2016 102 [12]
Staging/liver biopsy/fibroscan 2016 64 [12]
Screening costs as part of treatment (USD) Cost per screen 2016 12 [5]
Lab costs for F0-F3 2016 243 [5]
Lab costs for �F4 2016 243 [5]
Annual costs per diagnosed patient (USD) Follow-up costs for F0-F3 2016 888 [5]
Post-SVR12 healthcare costs for F0-F3 2016 23 [5]
Compensated cirrhosis 2016 1,132 [5]
Decompensated cirrhosis 2016 5,916 [5]
Hepatocellular carcinoma 2016 6,831 [5]
Liver transplant 2016 66,831 [5]
Post-liver transplant 2016 6,592 [5]
Extra-hepatic manifestations� 2017 693 [13]
�Extra-hepatic manifestations include: Arthritis, Depression, End-Stage Renal Disease, Glomeruloneprhitis, Heart Failure, Lichen Planus, Lymphoma, Myocardial
Infarction, Mixed Cryoglobulinemia, Porphyria Cutanea Tarda, Sjögren Syndrome, Stroke, Type II Diabetes, Cardiovascular Disease, and Chronic Renal Disease
https://doi.org/10.1371/journal.pone.0232186.t001
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4. Two-year delayed elimination: 24,000 newly diagnosed patients and 34,000 patients
treated annually, beginning in 2020.
5. Accelerated elimination: 42,000 newly diagnosed patients and 52,000 patients treated
annually, beginning in 2018. This scenario was designed to meet GHSS elimination targets
by 2025.
Results
Overall clinical and economic outcomes
An estimated 169,000 Koreans were infected with viremic HCV in 2017, of which 40%
(n = 70,000) had previously been diagnosed. About 4% (n = 6,300) of all infected Koreans
received treatment and achieved cure in 2017. Following the status quo, about 63,000 infected
Koreans are expected to remain undiagnosed and untreated by 2030. The four elimination
scenarios are projected to result in the diagnosis of all infected Koreans by 2030, with 100 or
fewer patients awaiting treatment. Compared to the status quo, elimination (regardless of
delay) also resulted in a decreased disease burden and lesser overall spending over 2017–2030.
However, the extent of the savings—measured in cases of disease, lives, and healthcare spend-
ing—is directly proportional to the rapid implementation of diagnosis and treatment practices
such that achieving elimination targets by 2025 led to the overall best outcomes (Fig 1). This
scenario requires an up-front investment in treatment and prevention, resulting in 1,400 lives
saved and 1.1 billion USD in savings (Fig 2).
Clinical analysis—Incident cases and cases averted
Accelerated elimination by 2025 resulted in the lowest number of cumulative incident cases
of HCV (n = 11,600) over 2017–2030 (Table 3 and Fig 1); nearly 3.5 times as many cases
occurred in the status quo scenario (n = 38,600), and 3,300–8,400 additional cases occurred
in all other scenarios. Accelerated elimination averted approximately 20–30% more HCV
incident cases (n = 27,000) compared to the one-year (n = 21,100) and two-year (n = 18,600)
delayed elimination scenarios, and over 10% more cases averted compared to elimination
(n = 23,700), with the status quo as the baseline. Total liver-related deaths (LRDs) were also
the lowest under the accelerated elimination (n = 800) and elimination (n = 880) scenarios;
however, all four elimination scenarios resulted in a substantial decrease in LRDs compared
to the status quo, with 660–1,400 deaths averted (Table 3 and Fig 1). All elimination scenar-
ios reduced the annual number of new LRDs to nearly zero during the study period, with the
earliest occurring by 2023.
Table 2. HCV-related intervention inputs implemented annually by scenario, 2017–2030�.
Scenarios Start year Newly diagnosed patients Annual treated patients
Status quo 2017 4,200 7,000
Elimination 2018 24,000 34,000
One-year delayed elimination 2019 24,000 34,000
Two-year delayed elimination 2020 24,000 34,000
Accelerated elimination 2018 42,000 52,000
�Assume no fibrosis stage restrictions (�F0), all ages eligible for treatment and an average sustained virologic
response after 12 weeks (SVR12) of 90% for all scenarios.
https://doi.org/10.1371/journal.pone.0232186.t002
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Fig 1. Change in cumulative incident cases of HCV, hepatocellular carcinoma, decompensated cirrhosis and total
liver-related deaths, by scenario, 2017–2030.
https://doi.org/10.1371/journal.pone.0232186.g001
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The fewest cumulative cases of ESLD are expected to occur if elimination (or accelerated
elimination) is initiated; 790 (n = 730) incident cases of DC and 1,100 (n = 990) incident cases
of HCC are projected by 2030. With a one-year delay in implementation (or two-year delay),
about 1,200 (n = 1,400) cases of DC and 1,600 (n = 1,900) cases of HCC are expected by 2030.
Fig 2. Change in annual and cumulative HCV liver-related costs, by scenario, 2017–2030.
https://doi.org/10.1371/journal.pone.0232186.g002
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As well, the elimination scenarios are projected to reduce cumulative new LTs between 60%–
80% over 2017–2030, relative to the status quo. Depending on the swiftness of implementation,
following the elimination plans could avert between 1,400–3,100 total cases of ESLD by 2030
(Table 3 and Fig 1). Notably, all elimination scenarios were estimated to reduce the annual
incident cases of HCV, DC, HCC and LT to nearly zero by 2030. This is expected to be unat-
tainable under the current standard of care.
Cost analysis—HCV liver-related complications, treatment and screening
Over the 2017–2030 study period, all elimination scenarios resulted in cumulative medical
cost savings associated with CHC infection in Korea: requiring between 2.7–3.3 billion USD in
total HCV spending compared to a cost of 3.8 billion USD projected under current healthcare
system. Accelerating elimination is expected to achieve the highest net savings of 1.1 billion
USD, achieving reduced total spending compared to the status quo by 2025 (Table 3 and Fig
3). To achieve these cost savings, a significant investment in preventative measures must be
implemented, with 160 million USD and 1.7 billion USD financing screening and treatment,
respectively. In this scenario, 800 million USD would be spent on liver-related complications
and EHM (360 and 450 million USD, respectively). Comparatively, continuing the status quo
would result in spending only 70 million USD on screening and 750 million USD on treat-
ment; however, liver-related complications and EHM would cost an additional 3.0 billion
USD by 2030 (1.2 and 1.8 billion USD, respectively) (Table 3 and Fig 3). Implementing stan-
dard, one-year delayed, or two-year delayed elimination targets increased spending incremen-
tally such that liver-related complications cost 470, 550 and 630 million USD, respectively, and
EHM cost 630, 760, 890 million USD, respectively. Postponing elimination severely impacted
net costs; a one-year delay dropped total cost savings over 40% and a two-year delay decreased
net cost savings by half (Table 3).
Table 3. Cumulative HCV-related clinical and economic outcomes by scenario, 2017–2030.







Incident cases of HCV (Cases averted�) 38,600 (0) 14,900
(23,700)
17,500 (21,100) 20,000 (18,600) 11,600 (27,000)
Total LRD (Deaths averted�) 2,200 (0) 880 (1,300) 1,200 (920) 1,500 (660) 800 (1,400)
New cases of DC 1,900 790 1,200 1,400 730
New cases of HCC 2,800 1,100 1,600 1,900 990
New cases of LT 100 20 30 40 17
Total cases of ESLD averted� 0 (2,900) (2,000) (1,400) (3,100)
Economic outcomes (in USD millions)
Total cost of liver-related complications 1,200 470 550 630 360
Total cost of extra-hepatic complications 1,800 630 760 890 450
Total treatment costs 750 1,700 1,700 1,600 1,700
Total screening costs 70 160 160 150 160
Total spending on HCV 3,800 2,900 3,100 3,300 2,700
Total costs saved compared to the status
quo
0 860 680 510 1,100
Hepatitis C virus (HCV), decompensated cirrhosis (DC), hepatocellular carcinoma (HCC); liver transplant (LT), decompensated cirrhosis (DC), liver-related deaths
(LRD), end-stage liver disease cases (ESLD) are a summation of DC, HCC and LT cases, United States dollar (USD).
�The number of cases averted describes cases for each outcome from the given scenario compared to the status quo (used as a baseline indicator).
https://doi.org/10.1371/journal.pone.0232186.t003
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Discussion
Until about 2015, HCV was an unfamiliar disease in Korea, even for some physicians. How-
ever, two major turning points occurred that brought CHC to the forefront of the conversa-
tion. Firstly, a number of HCV-related healthcare-associated outbreaks reported between 2015
(70 infected patients) and 2016 (95 infected patients) increased disease recognition and
prompted procedural changes [2, 15]. Beginning in September 2016, the Ministry of Welfare
and Health began investigating all suspect cases of HCV, and in June 2017, HCV reporting
became mandatory for all healthcare institutions. Prior to this, only 186 select medical institu-
tions were required to report cases. The second turning point was the progress of treatment
regimens with fewer side effects and markedly increased efficacy. Despite the availability of
protease inhibitors beginning in early 2010, about 25–41% of patients could not achieve SVR,
or ostensibly be “cured” [16]. In 2015, DAAs demonstrated SVR12 rates greater than 90% and
were approved and reimbursed in Korean patients with genotype 1b. As such, Korean hepatol-
ogists began regarding CHC as a curable disease.
Increased national recognition of HCV indicates that 1) intervention efforts are needed
now more than ever and 2) policymakers and healthcare workers may be particularly willing
to discuss intervention efforts at this time. This analysis evaluates and compares different
HCV elimination strategies with a goal of guiding next steps to reduce the burden of HCV in
Korea.
The overarching difference between the four elimination scenarios and the status quo sce-
nario relate to spending strategy over 2017–2030. In the status quo scenario, nearly 80% (3.0
billion USD) of the total HCV budget (3.8 billion USD) was spent on HCV liver-related com-
plications. For all elimination scenarios, 55–70% (1.8–1.9 billion USD) of the HCV budget
(2.7–3.3 billion USD) was instead invested in prevention. The difference between spending
strategies is either an investment in prevention (elimination scenarios) or a focus on disease
Fig 3. Change in cumulative cost of HCV liver-related complications, by scenario, 2017–2030.
https://doi.org/10.1371/journal.pone.0232186.g003
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mitigation and cure that is required due to lack of prevention, which also results in a less
healthy Korea (status quo scenario). Postponing intervention by just one or two years led to
worse clinical outcomes and a substantial increase in spending. The total number of LRD
increased about 65% when comparing the standard elimination strategy to a two-year delay.
Cost savings declined as the elimination plan was postponed, with savings decreased by half
between the accelerated and two-year delayed strategies (Fig 2). The best-case scenario is
implementation of accelerated elimination targets: saving money while reducing wasted
expenditure on preventable complications. In this scenario, costing 2.7 billion USD, 70% of
total funds (1.9 billion USD) would support national treatment and screening.
Regardless of the elimination scenario, additional spending is needed to continue or
enhance HCV-related services to the public. Meeting accelerated elimination requires an
increase in spending from the status quo by 98% in the first year of implementation. Compara-
tively, standard or delayed elimination warranted a 52–57% increase in spending in the first
year of the program. While accelerated elimination requires a substantial initial investment,
annual costs would reach that of the status quo in 2021 and continue to decline rapidly, well
below the cost of the current strategy (Fig 2). In terms of surge capacity, there is a marked
effect. In the third year of the accelerated elimination scenario (the year 2020), annual spend-
ing (500 million USD) would fall below the starting cost of the two-year delayed elimination
plan (550 million USD) which begins in 2020. This demonstrates how rapid implementation
is key, since postponing interventions by two years results in half the savings by 2030 and
increased disease burden.
Historically, Korea has successfully leveraged government policy to manage infectious dis-
ease spread [17]. In 1995, Korea implemented universal hepatitis B virus (HBV) vaccination
for newborns to prevent perinatal transmission. Coverage rates for the three-dose HBV series
rapidly increased to 98% and have been sustained at this rate as of 2017 [18]. HBV vaccine
introduction, along with other prevention methods, is attributed to decreasing HBV preva-
lence from 10% in the 1980s to about 2.9% in 2015 and diminishing the threat to middle-aged
and younger populations [19, 20]. Although no vaccine exists for HCV, the success of strong
government policy can be leveraged to target CHC in Korea. Case-finding is an integral first
step, especially due to a diagnosis coverage of as low as 10% in the general population [21].
This study shows that accelerating elimination is the most effective method to reduce
both the economic and disease burden of CHC. Similar result have been demonstrated in
other analyses [22, 23]. Under the current standard of care, Korea is not projected to achieve
HCV elimination by 2030. Current diagnostic and treatment practices must be increased
nearly 4.5-fold and 3-fold, respectively, to achieve targets by 2025. In this respect, aggressive
screening and linkage to care are the most important components of successful disease con-
trol, with the added benefits of saving money and lives. Unfortunately, no nationwide effort
exists to diagnose asymptomatic cases, and HCV antibody testing is currently performed
only at the patients’ request. Implementation of a national screening program, however,
would provide a broad platform to ramp-up and expand screening efforts. Local experts also
agree that screening is the key step to reach elimination and suggest that including HCV
antibody screening in the free annual health check-up program provided by KNHIS could
be an important case-finding tool [12]. However, the government body is hesitant to adopt
HCV testing into the national health check-up program because of potential costs. This
study’s results should serve as the backbone for policy and decision-making, demonstrating
how aggressive prevention measures are designed to reduce future costs and increase the
health of the public. Furthermore, KNHIS covers most currently available DAAs without
restriction to cirrhosis or fibrosis level. Therefore, once patients are aware of their status,
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they may be more likely to seek treatment due to the absence of a cost barrier. Given this,
screening will be the most important element of successful disease elimination.
Strengths and limitations
The Markov model is calibrated with Korea-specific HCV data using previously published dis-
ease progression rates, which strengthens the analysis. As a subcomponent, the Impact of Inac-
tion platform is simplified for ease of use but also allows for the flexibility of manipulating
multiple intervention scenarios. It is based in Microsoft Excel1 to provide transparency and
accessibility by external partners.
The analysis contains several limitations. Although prevalence estimates were obtained
from the best available data in the literature, actual values may vary across settings and patient
subgroups. Cost data were available for several additional medical conditions potentially asso-
ciated to EHM; however, these were excluded due to a weak association with HCV and because
they are not used in similar disease burden analyses. However, if these costs were included, we
would expect even greater cost-savings under an elimination strategy. The societal outcomes
of these scenarios, such as loss of productivity or quality-adjusted life years, were not consid-
ered. However, inclusion would likely support the case for aggressive prevention since
decreased prevention is correlated with increases in morbidity and mortality. Additionally,
due to the limits inherent in prediction, the model may not reflect observed results. Advance-
ments in science could affect the types of diagnostics or treatment available for HCV in the
upcoming decades, which could alter projected outcomes. As well, economic changes would
influence the cost of HCV treatment and prevention in the future. Rather than operating as a
detailed plan for intervention, results should support decision-making.
Factors influence the cascade of HCV care in Korea, such as linking diagnosed patients to
care, treatment initiation and treatment retention, are poorly understood. Thus, even if accel-
erated screening was performed as designed in the scenarios, unexpected problems may occur
regarding treatment uptake. Additional research may be needed to adequately understand the
gaps in HCV care to inform and refine elimination strategies.
Conclusions
By leveraging tools that quantify the impact of HCV screening and treatment interventions,
Korea would avert a significant portion of incident cases, end-stage liver disease and death
from HCV, and reduce costs. Postponing this intervention by just one or two years would lead
to increased spending and fail to avert preventable hepatic complications and new infections,
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